Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Clinical trial NCT03192397 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03192397
Sponsor: Roswell Park Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia in Remission Adult Acute Lymphoblastic Leukemia in Complete Remission Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission Chronic Myelomonocytic Leukemia in Remission Graft Versus Host Disease Hodgkin Lymphoma Minimal Residual Disease Myelodysplastic Syndrome Myeloproliferative Neoplasm Non-Hodgkin Lymphoma Plasma Cell Myeloma Severe Aplastic Anemia

Start date: 2017-08-09
Primary completion: 2023-08-21
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.